This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the safety and efficacy of Deferiprone in participants with Alzheimer's disease. In this study, the investigators aim to determine whether Deferiprone (15 mg/kg BID orally) slows cognitive decline in Alzheimer's patients.
Florey Institute scientists have demonstrated that cognitive abilities like short term memory, executive function and language ability decline much faster in people with both high iron levels and high amyloid levels, than those with low brain iron levels who were also amyloid positive.
We are looking for adults to join the study, who:
- Are aged over 65, or aged over 55 years and have been diagnosed with Alzheimer's disease or are amyloid positive
- Have a reliable care support person for 12 months of the trial
- Have demonstrated abnormal memory function in the last 6 months or at screening
- If they have been on medication for symptomatic Alzheimer's disease, must be on a stable dose for the last 3 months
Participants will be screened for the study after signing the approved informed consent form. As part of the screening phase, subjects will undertake an extensive medical and neurological assessments as well as a PET and MRI scan.
Participants will need to take an oral medication (Deferiprone) twice a day for 52 weeks. Participants will return to the trial centre on Weeks 13, 26, 38, 52 to undertake a neurological examination as well as an assessment of blood samples taken at the visit. Participants must also attend weekly blood tests for the first 6 months of the trial, then fortnightly for the remaining 6 months. The blood test can be collected at pathology service near your place of residence.